Is the brand‑name medication Fexiclue (dexlansoprazole) pharmacologically equivalent to fexuprazan and interchangeable for treating severe gastro‑oesophageal reflux disease?

No, Fexiclue and Fexuprazan Are NOT Pharmacologically Equivalent or Interchangeable

Fexiclue (based on the FDA label provided) appears to be a topical external-use product 1, while fexuprazan is an oral potassium-competitive acid blocker (P-CAB) used for gastroesophageal reflux disease 2. These are completely different medications with different routes of administration, mechanisms of action, and therapeutic indications—they cannot be substituted for one another.

Critical Clarification on Drug Identity

The confusion may stem from similar naming, but the evidence clearly distinguishes these as separate entities:

• Fexiclue: The FDA label indicates this is for "external use only" and applied to "affected area not more than 3 to 4 times daily" 1—this is a topical preparation, not a gastric acid suppressant

• Fexuprazan: This is an oral P-CAB that reversibly inhibits the K+/H+-ATPase enzyme in gastric parietal cells, providing rapid and sustained acid suppression 3, 4

• Dexlansoprazole: This is a proton pump inhibitor (PPI), the R-enantiomer of lansoprazole, with a dual delayed-release formulation 2, 5

For Severe GERD: Fexuprazan vs. Dexlansoprazole

If your actual question concerns choosing between fexuprazan (P-CAB) and dexlansoprazole (PPI) for severe GERD:

When to Use Fexuprazan

Use fexuprazan in patients with severe erosive esophagitis (LA grade C/D) who have failed twice-daily PPI therapy 2. The 2024 AGA guidelines specifically recommend P-CABs may be used in selected patients with documented acid-related reflux who fail twice-daily PPIs 2.

• Fexuprazan 40 mg demonstrated non-inferiority to esomeprazole 40 mg for healing erosive esophagitis at 8 weeks (99.1% vs 99.1%) 4
• P-CABs provide more potent and sustained acid suppression than PPIs, with longer half-lives (6-9 hours vs 1-2 hours) and no requirement for premeal dosing 2
• Fexuprazan does not require CYP2C19 metabolism, avoiding genetic variability issues seen with PPIs 3

When to Use Dexlansoprazole

Use dexlansoprazole as first-line therapy for mild-to-moderate GERD (LA grade A/B erosive esophagitis) or nonerosive reflux disease 2.

• Dexlansoprazole 60 mg is highly effective for healing erosive esophagitis and controlling symptoms, with particular efficacy for nocturnal heartburn 5, 6
• The dual delayed-release formulation provides extended acid suppression and can be taken without regard to meals 6
• Dexlansoprazole is more cost-effective than P-CABs and has more robust long-term safety data 2

Clinical Algorithm for Severe GERD

1. First-line: Start with dexlansoprazole 60 mg once daily or standard-dose PPI twice daily
2. PPI failure: If inadequate response after 8 weeks of twice-daily PPI, confirm acid-related reflux with pH monitoring or endoscopy
3. Escalation: Switch to fexuprazan 40 mg once daily for documented severe erosive esophagitis (LA grade C/D) or PPI-refractory symptoms 2

Important Caveats

• Cost considerations: P-CABs like fexuprazan are markedly more expensive than PPIs and often require prior authorization 2
• Limited long-term data: P-CABs have less robust long-term safety data compared to PPIs 2
• Not for mild disease: The 2024 AGA guidelines recommend against using P-CABs as first-line therapy for milder erosive esophagitis (LA grade A/B) 2
• Gastrin elevation: Long-term P-CAB use may increase serum gastrin levels, though clinical significance remains unclear 7

The bottom line: Fexiclue (as labeled) is not interchangeable with fexuprazan. For severe GERD, use fexuprazan only after documented failure of twice-daily PPI therapy, while dexlansoprazole remains appropriate first-line therapy for most patients 2.